Testing glofitamab plus chemo for lymphoma in the brain or spinal cord
Original title: Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the drug mix is still being tested in people.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests a drug mix for lymphoma that has spread to the brain or spinal cord.
Who this trial is for. This trial is for people whose lymphoma came back or did not respond to past treatment, and has spread to the brain, spinal cord, spinal fluid, or eye. It tests a drug called glofitamab along with two chemo drugs, gemcitabine and oxaliplatin.
Where it stands. The trial has not reported results. It plans to measure how many people's lymphoma responds to this drug mix. It will also track how long those responses last, and what side effects happen. Everyone in the trial gets the treatment every 3 weeks for up to 6 cycles. The answers are not in yet.
What this means, and what it doesn't
What it could mean: There is no agreed standard treatment once this kind of lymphoma comes back. A trial is one more option to ask about. If this sounds like your situation, you can ask your care team about it. They can help you think it through.
What it doesn't mean: This drug mix is a test, not a proven treatment. Being in a trial is not a promise that it will help you. It is not a promise of a cure. The treatment may not work, and it may cause side effects. The trial team decides who can join.
Source: ClinicalTrials.gov, October 22, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.